Sacra estimates that AIOS hit $420M in annualized gross revenue in June 2026, up from $125M at the end of 2025.

AIOS launched in July 2021 as Fella Health, a GLP-1 telehealth brand for men, and grew slowly until the FDA approved compounding during the semaglutide shortage in 2022, allowing it to charge roughly $300 per month versus Wegovy's $1,300 sticker price. That compounding window took the business from $74K in annualized revenue in 2021 to $36M at the end of 2024, with the broader AIOS entity crossing $50M in annualized revenue in November 2024.

When the FDA resolved the semaglutide shortage in early 2025 and Eli Lilly and Novo Nordisk sued Fella alongside other GLP-1 telehealth businesses including Mochi Health and Henry Meds, annualized revenue fell from $82M in March 2025 to $54M in September 2025. The recovery came through the April 2025 acquisition of UK online pharmacy Bolt, which let AIOS apply its paid-growth playbook to Britain's private cash-pay market for branded Wegovy and Mounjaro.

AIOS grew from roughly $10M in annualized UK GLP-1 revenue in July 2025 to $100M in December 2025, then to $350M ARR in July 2026, serving more than 150,000 monthly patients. The implied revenue per active patient runs approximately $190 per month, consistent with Bolt's published pricing of £25-£42 per week and Fella's US pricing of $99-$199 per month.

The business has been profitable since 2023 and has raised no institutional capital beyond its seed round from Y Combinator and Global Founders Capital. Revenue quality is constrained by the decision to sell branded drugs at cost: Bolt takes no markup on the medication itself, passing the bulk of gross revenue through to Eli Lilly and Novo Nordisk, yielding gross margins of roughly 20% versus the 65-80% that Ro and Hims & Hers earn on fulfillment.

AIOS raised a seed round through Y Combinator's W20 batch, with participation from Global Founders Capital, Streamlined Ventures, AngelList Early Stage Fund, and BrandProject. The only publicly confirmed seed-stage capital on record totals $130K.

AIOS is a vertically integrated digital clinic focused on GLP-1 obesity care. Patients enter through consumer brands such as Bolt Pharmacy in the UK or Fella Health in the US, complete a short online eligibility questionnaire, and receive a clinical review from a registered prescriber. If approved, medication is dispensed by a regulated pharmacy and shipped to the patient's door, with dose titration, refill management, and ongoing support handled in the same workflow.

Its core software is ClinicOS, a clinical operating system that converts prescribing logic into structured decision trees, including BMI thresholds, contraindication checks, titration schedules, and side-effect escalation pathways. The system moves patients from intake through clinical review, approval, and fulfillment with minimal human intervention in routine cases, while routing edge cases to a network of 50-plus prescribing pharmacists and clinicians.

For patients, the Bolt iOS app provides prescription and delivery tracking, weight-loss logging, dose scheduling, reminders, and reordering. For clinicians, an internal dashboard presents structured case summaries, decision-support logic, and refill workflows, increasing the patient volume each prescriber can manage relative to a traditional async telemedicine model.

AIOS also builds internal tools for operations and customer experience. These tools target common retention failures in telemedicine, including incomplete forms, delayed shipments, missed dose transitions, and slow responses to side effects. The product objective is to deliver an e-commerce-like experience within a regulated clinical service.

The product today is better described as AI-assisted and workflow-automated than fully autonomous. Clinicians remain accountable for prescribing decisions, while the software is designed to reduce the marginal human time required per patient as protocols mature and automation expands.

AIOS is a vertically integrated, direct-to-consumer healthcare brand rather than a pure software vendor or traditional telemedicine platform. It acquires patients through paid performance marketing under its owned brands, converts them through a digital intake and clinical review flow, and monetizes through recurring monthly treatment programs that bundle medication access, clinical oversight, and ongoing support into a single subscription price.

Because AIOS sells branded GLP-1s at cost in the UK, taking no markup on Wegovy or Mounjaro, the gross margin profile looks more like a pharmacy than a software business, running around 20% versus the 65–80% that fully integrated telehealth players like Ro and Hims & Hers earn when they control fulfillment economics. The logic of at-cost pricing is volume and speed: by undercutting UK pharmacies like Numan and Boots, which charge £179–£299 per month, Bolt became the cheapest regulated source of branded GLP-1s in Britain and grew its active patient base from 3,000 to 150,000 in twelve months.

The cost structure differs from most consumer health businesses. Because ClinicOS automates much of the routine clinical workflow, AIOS can spread a relatively small prescriber headcount across a very large patient base, reducing the labor intensity that makes traditional telemedicine hard to scale profitably. Customer acquisition remains the largest variable cost, and the company's heavy investment in paid growth infrastructure shows how dependent the model is on performance marketing.

The longer-term architecture has two layers. The first is the owned-brand business, Bolt, Fella, and future country-specific brands, which generates cash and operational data. The second is ClinicOS as potential infrastructure for external healthcare brands, though that platform layer remains nascent relative to the owned-brand revenue today.

AIOS competes across three overlapping arenas: vertically integrated consumer telehealth, UK and European obesity specialists, and the emerging market for AI-native clinical workflow infrastructure. No single rival competes across all three at once, but each category creates real competitive pressure.

Hims & Hers and Ro are the clearest large-scale analogues. Hims & Hers, which generated $2.2B in trailing twelve-month revenue growing 50% year over year, built its business by stacking conditions, ED, hair loss, dermatology, weight loss, onto a single consumer brand. AIOS is taking the opposite approach, betting that GLP-1s alone are a large enough market to scale one molecule across segments on a shared ops layer.

Ro has moved furthest toward the infrastructure model AIOS is pursuing, marketing its own clinical operating system as a vertically integrated stack spanning telehealth, pharmacy, lab, and insurance concierge. Ro also locked in Wegovy supply through Novo Nordisk's NovoCare pharmacy at £410 per month in the UK, competing on supply credibility rather than price. Hims & Hers entered the UK by acquiring London-based online doctor ZAVA in June 2025, giving it a CQC-regulated footprint and an existing patient base.

Numan, Juniper, and ZAVA are the most direct local competitors in the market where AIOS is growing fastest. Numan is CQC-regulated, serves hundreds of thousands of patients, and has built an AI health assistant, but charges £179-£299 per month, well above Bolt's pricing. Juniper, operated by Eucalyptus, already runs regulated obesity telehealth across the UK, Germany, Japan, and Australia, which suggests the multi-market playbook AIOS wants to execute is viable but requires local operational infrastructure in each jurisdiction.

ZAVA, which claims 200,000 weight-loss patients treated and calls itself the UK's leading weight-loss provider, competes on workflow speed and fulfillment trust rather than AI positioning. Its traction indicates that patients in this category primarily want reliable access and supply continuity, not a frontier-AI story.

The most structurally threatening competitive dynamic is Eli Lilly and Novo Nordisk moving downstream into direct patient access. LillyDirect and NovoCare are early examples of manufacturers treating telehealth as a controlled go-to-market layer rather than an independent channel.

If pharma increasingly routes patients through preferred partners, as Novo Nordisk did with Hims & Hers in 2026, AIOS may find its biggest competitive threat is not another startup but a distribution stack co-designed by manufacturer and scaled platform, one that could squeeze out at-cost resellers entirely.

AIOS's expansion logic starts with a high-frequency wedge, GLP-1 obesity care, and extends along three axes: new formulations and adjacent conditions, geographic replication of the Bolt playbook, and eventual commercialization of its internal clinical operating system as external infrastructure.

The June 2026 UK approval of the first oral GLP-1 tablet for weight loss creates an immediate product expansion opportunity. Oral formulations lower friction for patients unwilling to start injectables, widening the addressable population without requiring AIOS to rebuild its intake, clinical review, or fulfillment infrastructure. Bolt's existing help materials already educate patients on oral Wegovy, which suggests the commercial layer can absorb the new modality quickly.

A second adjacency is longitudinal metabolic health. Patients already on GLP-1s for weight loss often present with prediabetes, dyslipidemia, hypertension, and sleep apnea, conditions that fit the same intake data, async clinical review model, and recurring prescription cadence that AIOS has already built. Moving from episodic weight-loss prescriptions into ongoing metabolic disease management would increase patient lifetime value and extend the clinical relationship beyond a single molecule.

AIOS's stated plan is to replicate the Bolt acquisition playbook across Europe's ten largest markets, buying a licensed local pharmacy in each, plugging it into ClinicOS, and undercutting incumbents on price. Europe is attractive because GLP-1 adoption is still early in most markets, NHS-style rationing creates large private cash-pay populations, and regulatory fragmentation has slowed expansion by well-capitalized US players.

The UK-to-Europe expansion follows logic similar to Eucalyptus building Juniper across four countries, but AIOS's at-cost pricing strategy gives it a sharper wedge in markets where branded drug prices are nationally anchored. Each new country adds incremental fixed cost for regulatory compliance and local pharmacy operations, while clinical workflow, software, and growth infrastructure are shared across the platform.

AIOS describes ClinicOS as infrastructure that can power external consumer healthcare brands, not just its own. Under this model, third-party brands such as retailers, wellness companies, and employer benefit providers would use AIOS as the regulated clinical and fulfillment backbone rather than build their own prescribing infrastructure. The sequencing resembles Ro's approach with ro.OS, moving from owned brands first to a later platform layer.

This layer depends on AIOS proving better throughput, conversion, or cost per patient in its owned brands before third parties adopt the full stack. If ClinicOS can show that it handles intake, prescribing, fulfillment, and retention at a cost structure external brands cannot replicate independently, the platform business becomes an extension of the existing operator model rather than a separate product bet.

GLP-1 concentration: AIOS's revenue base, growth narrative, and path to manufacturing economics depend on a single drug class, so any sustained compression in GLP-1 pricing, a supply disruption from Eli Lilly or Novo Nordisk, or demand normalization after the initial obesity-treatment boom would hit revenue, erode the at-cost pricing advantage, and slow the patient-volume accumulation that funds European expansion.

Manufacturer disintermediation: As Lilly and Novo Nordisk build direct-to-consumer access channels like LillyDirect and NovoCare and sign preferred-partner agreements with scaled telehealth platforms like Hims & Hers, AIOS risks being squeezed out of the supply chain entirely, either through reduced access to branded drugs on economic terms it can support or lower inventory allocation in favor of partners that generate more manufacturer-controlled margin.

Autonomy gap: AIOS's long-term margin thesis depends on achieving near-zero marginal human time per patient through autonomous prescribing, but current healthcare regulation across every market where it operates requires licensed human accountability for prescribing decisions, so the company must sustain a labor-heavy clinical staffing model until regulators in the UK, EU, and US explicitly authorize the autonomous workflows its software is already designed to run.